Krsnaa Diagnostics Ltd (KRSNAA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Krsnaa Diagnostics Ltd on NSE and BSE, with an AI summary of each filing.
Intimation of Change in Corporate office of Registrar and Sahre Trasnfer Agent of the Company w.e.f. 1st December 2026.
Others (Uncategorized) · 04 Nov 2026, 12:28 am
Krsnaa Diagnostics Reports Relocation of RTA KFin Technologies Corporate Office Krsnaa Diagnostics has informed exchanges that its Registrar and Share Transfer Agent (RTA), KFin Technologies Limited, is relocating its Corporate Office effective 1st Dec'26. The new office is situated at Rajapushpa West Avenue, Kokapet, Hyderabad, Telangana (500075), shifting from its previous premises in Gachibowli, Nanakramguda. The registered office of the RTA remains unchanged. All future correspondence and business communications regarding RTA corporate operations will be directed to the updated facility.
Audio recording of conference call for the quarter and half year ended September 30, 2026
Audio / Video · 04 Nov 2026, 12:14 am
Krsnaa Diagnostics Releases Q2FY27 Earnings Conference Call Audio Recording Krsnaa Diagnostics Limited announced that the audio recording of its earnings conference call for the quarter and half-year ended 30th Sep'26 (Q2FY27), conducted on 3rd Nov'26 at 12:30 IST, is now available on the company's official website pursuant to Regulation 30 of SEBI LODR Regulations.
Submission of Certificate obtained from Statutory Auditors in terms of Regulation 169(5) of the SEBI ICDR Regulations, 2018
Others (Uncategorized) · 03 Nov 2026, 11:41 pm
Krsnaa Diagnostics Receives Auditor Certification for Rs 91.75 Cr Promoter Warrants Issue Krsnaa Diagnostics submitted a statutory auditor certificate from Kirtane & Pandit LLP on 3rd Nov'26 confirming regulatory compliance under SEBI ICDR Regulations for issuing 16,21,000 convertible share warrants at an issue price of Rs 566 per share (face value Rs 5) on a preferential basis to its Promoter and Promoter Group. The total warrant issue value stands at Rs 91.75 Cr, with 25% upfront consideration totaling Rs 22.94 Cr successfully received in full from allottees Rajendra Mutha (75,000 warrants) and Krsnaa Diagnostics (Mumbai) Pvt. Ltd. (15,46,000 warrants).
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Krsnaa Diagnostics secures 15 year Cash based PPP project from Municipal corporation of Delhi for Advanced CT Scan and ....
Others (Uncategorized) · 03 Nov 2026, 8:03 pm
Krsnaa Diagnostics Secures 15-Year Cash-Based PPP Project from MCD Krsnaa Diagnostics received a Letter of Award on 2nd Nov'26 from the Municipal Corporation of Delhi to finance, establish, operate, and maintain advanced CT Scan and MRI facilities across three public hospitals in Delhi under a cash-collection Public-Private Partnership model. The concession spans 10 years from the Commercial Operation Date, extendable by up to 5 years. The Service Provider Agreement must be executed within 30 days, with commercial operations targeted within 180 days of site handover. Revenue will be volume-dependent based on investigations conducted.
Investor Presentation for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2026
Investor Presentation · 03 Nov 2026, 12:16 am
Krsnaa Diagnostics Reports Robust Q2 FY27 Topline Growth of 32% YoY Krsnaa Diagnostics delivered strong performance for Q2 FY27, with revenue growing 32% YoY to INR 2,710 mn, driven by an 85% YoY surge in tests performed (30.3 mn) and a 35% YoY increase in patients served (7.3 mn). Retail revenue rose 35% YoY to INR 235 mn. EBITDA (pre-CSR/ESOP) increased 20% YoY to INR 719 mn, while margins contracted 200 bps to 27% due to upfront fixed costs for Rajasthan labs. PAT rose 3% YoY to INR 246 mn. For H1 FY27, revenue reached INR 5,065 mn.
Press Release - Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2026
Press Release · 03 Nov 2026, 12:08 am
Krsnaa Diagnostics Reports Record Q2 FY27 Revenue Up 32% YoY Krsnaa Diagnostics reported its highest-ever quarterly revenue of Rs 2,710 million for Q2 FY27, up 32% YoY, while H1 FY27 revenue rose 27% YoY to Rs 5,065 million. Q2 FY27 EBITDA grew to Rs 719 million with margins at 27%, and PAT reached Rs 246 million. Retail revenue expanded 35% YoY to Rs 235 million, representing ~9% of total revenue on a 48% increase in test volumes. Upfront costs for the Rajasthan PPP project temporarily moderated H1 PAT, with anticipated operational benefits accruing in subsequent quarters.
Financial Results for Quarter and Half Year ended September 30, 2026
Financial Result · 02 Nov 2026, 8:45 pm
Krsnaa Diagnostics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 02 Nov 2026, 8:38 pm
Outcome of Board Meeting for Q2 FY 2026-27
Outcome · 02 Nov 2026, 8:36 pm
Outcome of Board Meeting for Q2 FY 2026-27
Outcome · 02 Nov 2026, 8:36 pm
Krsnaa Diagnostics Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 2,710 (+31.5% YoY | +15.0% QoQ) ■ EBITDA: 711 (+20.2% YoY | +22.7% QoQ) ■ EBITDA Margin (%): 26.2 (-247 bps YoY | +163 bps QoQ) ■ PAT: 246 (+2.7% YoY | +48.6% QoQ) ■ EPS (INR): 7.54 (+4.0% YoY | +49.6% QoQ)
Investor Call Updates - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation · 27 Oct 2026, 10:22 pm
Krsnaa Diagnostics Schedules Q2 and H1 FY27 Post-Earnings Conference Call Krsnaa Diagnostics Ltd. will host its post-earnings conference call on 3rd Nov'26 at 12:30 PM IST to discuss financial results for the quarter and half-year ended 30th Sep'26 (Q2 & H1 FY27). The call will feature Managing Director Yash Mutha, Group CEO Mitesh Dave, and Interim CFO Chandra Prakash, followed by an interactive Q&A session. Audio recordings and transcripts will be published on the company's website subsequently.
Krsnaa Diagnostics Limited has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
Krsnaa Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 02 Nov 2026, 5:30 am
Krsnaa Diagnostics Schedules Board Meeting for Q2 Financial Results Krsnaa Diagnostics Limited announced that its Board of Directors is scheduled to meet on 2nd Nov'26. The board will inter-alia consider and approve the unaudited standalone and consolidated financial results of the company for the quarter and half year ended 30th Sep'26, in compliance with SEBI Listing Regulations.
Press Release on Strategic AI Collaboration with AZMed
Press Release · 22 Oct 2026, 1:04 pm
Krsnaa Diagnostics Partners with AZmed to Integrate AI in Radiology Operations Krsnaa Diagnostics announced a strategic collaboration with European MedTech firm AZmed to evaluate its FDA-cleared and CE-marked AI solution, AZtrauma, for X-ray fracture detection and triage. Processing over 5 million X-rays annually across its network of 2,000+ X-ray centres, Krsnaa aims to leverage AI integration to enhance radiologist productivity, reporting efficiency, and unlock operating leverage across its public-private partnership diagnostic footprint. The implementation remains subject to successful evaluation and regulatory approvals.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Krsna Diagnostics (Mumbai) Pvt Ltd & PAC
Acquisition/ Disposal of Shares · 16 Oct 2026, 3:55 pm
Krsna Diagnostics Promoter Group Allotted Convertible Warrants via Preferential Basis Promoter group entities of Krsna Diagnostics Ltd, including Krsna Diagnostics (Mumbai) Pvt Ltd (15.46 lakh warrants) and Rajendra Mutha (0.75 lakh warrants), were allotted 16.21 lakh fully convertible warrants on 13th Oct'26. The preferential allotment was priced at ₹566 per warrant, with 25% received upfront. Post-allotment, the promoter and PAC holding stands at 87.96 lakh equity shares (27.11% voting capital; 25.08% diluted) and increases to 1.04 crore equity shares (29.70% of total diluted share capital) assuming full warrant conversion.
Clarification on Allotment of fully Convertible Warrants on a Preferential Basis
Others (Uncategorized) · 14 Oct 2026, 7:36 pm
Krsnaa Diagnostics Clarifies Preferential Warrant Premium Pricing Krsnaa Diagnostics issued a clarification regarding its 13th Oct'26 intimation on the allotment of fully convertible warrants on a preferential basis. The company corrected a typographical error concerning the issue premium, stating that the premium per warrant is ₹561 instead of the previously reported ₹551 per warrant. All other terms and details from the original intimation remain unchanged.
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Allotment of Fully Convertible Warrants
Others (Uncategorized) · 14 Oct 2026, 12:41 am
Krsnaa Diagnostics Allots Preferential Warrants Worth ₹91.75 Crore to Promoters Krsnaa Diagnostics allotted 16,21,000 fully convertible warrants on 13th Oct'26 at ₹566 each on a preferential basis to promoters, receiving an upfront 25% subscription amount of ₹22.94 crore. Allottees include promoter Rajendra Mutha (75,000 warrants) and promoter entity Krsna Diagnostics (Mumbai) Private Limited (15,46,000 warrants). The warrants are convertible into equity shares (face value ₹5) within 18 months upon paying the remaining 75%. Post-conversion, promoter and promoter group shareholding will increase from 27.11% to 29.70%.
Intimation of the In-Principle Approval Letter from BSE for issue of 16,21,000 Convertible Warrants to Promoter and Promoter Group of the Company
Others (Uncategorized) · 10 Oct 2026, 12:49 am
Krsnaa Diagnostics Receives BSE Approval for 16.21 Lakh Promoter Warrants Krsnaa Diagnostics received a corrected in-principle approval letter from BSE Ltd on 9th Oct'26 for the preferential issue of 16,21,000 warrants convertible into an equivalent number of equity shares (face value Rs. 5 each) to its Promoter and Promoter Group. The issue price is fixed at Rs. 566 per warrant, totaling approximately Rs. 91.75 Cr. The updated approval rectifies factual errors from an earlier letter. The allotment remains subject to standard statutory compliances and subsequent post-issue listing formalities within stipulated exchange timelines.
Intimation of receipt of In-Principle Approval received for issue of Warrants
Others (Uncategorized) · 09 Oct 2026, 3:11 am
Krsnaa Diagnostics Receives In-Principle Approval for Preferential Convertible Warrants Issue Krsnaa Diagnostics Limited received in-principle approval from BSE and NSE on 8th Oct'26 to issue 16,21,000 convertible warrants on a preferential basis to its Promoter and Promoter Group under Regulation 28(1) of SEBI LODR. Each warrant is convertible into one equity share of face value Rs. 5 each at an issue price of Rs. 566 per share, aggregating to approximately Rs. 91.75 crore. A rectified approval letter from BSE will be submitted separately due to factual errors in the initial communication.
Intimation of receipt of In-Principle Approval received for issue of 16,21,000 warrants convertible into 16,21,000 Equity Shares
Others (Uncategorized) · 09 Oct 2026, 2:45 am
Krsnaa Diagnostics Receives In-Principle Approval for Convertible Warrants Issue Krsnaa Diagnostics secured in-principle approval from BSE and NSE on 8th Oct'26 for the preferential issuance of 16,21,000 convertible warrants to its Promoter and Promoter Group. Each warrant is convertible into one equity share of face value Rs. 5 at an issue price of Rs. 566 per share. While NSE approval is finalized, BSE's letter contains factual errors undergoing rectification, with the corrected version to be submitted upon receipt.
Submission of revised Voting results.
Annual General Meeting · 01 Oct 2026, 1:55 am
Krsnaa Diagnostics Submits Revised AGM Voting Results With Key Resolutions Approved Krsnaa Diagnostics issued a revised Regulation 44(3) filing on 30th Sep'26 to correct a clerical error regarding promoter interest, confirming it had no impact on voting outcomes. Shareholders approved all ordinary resolutions at the 16th AGM held on 28th Sep'26 with requisite majorities. Key approvals include the adoption of FY26 audited financial statements, a final dividend of INR 2.00 per share (40% of face value INR 5), the re-appointment of director Yash Mutha, and the appointment of M/s Kirtane & Pandit LLP as statutory auditors.
Intimation for Change in Statutory Auditors of the Company
Change in Auditor · 30 Sept 2026, 6:53 pm
Krsnaa Diagnostics Appoints Kirtane & Pandit LLP as Statutory Auditor for Five-Year Term Shareholders of Krsnaa Diagnostics Limited approved the appointment of M/s Kirtane & Pandit LLP, Chartered Accountants, as Statutory Auditors at the 16th AGM held on 28th Sep'26. The appointment is for a first term of five consecutive years, running from the conclusion of the 16th AGM until the conclusion of the 21st AGM. Kirtane & Pandit LLP brings over seven decades of experience in audit, risk management, and tax advisory services.
Scrutinizer''s Report and Voting Results of 16th Annual General Meeting of the Company
Annual General Meeting · 30 Sept 2026, 6:12 pm
Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 29 Sept 2026, 12:27 am
Krsnaa Diagnostics Approves Diagnostic Equipment Sale Up to ₹120 Crore Krsnaa Diagnostics' Board approved the sale of identified diagnostic equipment for up to ₹120 crore on 28th Sep'26. The move aligns with its transition toward an asset-light, capital-efficient operating model, aiming to unlock value, recycle capital into core operations, enhance ROCE, and strengthen the balance sheet without affecting core capabilities. The freehold assets carry no lender encumbrances, and the transaction is not driven by asset impairment, with management expecting no material adverse impact on the profit and loss account or ongoing operations.